Study to Investigate the Efficacy and Safety of FAB122 (Daily Oral Edaravone) in Patients With Amyotrophic Lateral Sclerosis (ADORE)
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of FAB122 in Patients With Amyotrophic Lateral Sclerosis
Sponsor: Ferrer Internacional S.A.
This PHASE3 trial investigates Amyotrophic Lateral Sclerosis and is currently completed. Ferrer Internacional S.A. leads this study, which shows 8 recorded versions since 2021 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Apr 2025 — Sep 2025 [monthly]
Completed PHASE3
-
Oct 2024 — Apr 2025 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Sep 2024 — Oct 2024 [monthly]
Active Not Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE3
▶ Show 3 earlier versions
-
Feb 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Nov 2022 — Feb 2023 [monthly]
Recruiting PHASE3
-
Feb 2022 — Nov 2022 [monthly]
Recruiting PHASE3
First recorded
Oct 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ferrer Internacional S.A.
- Julius Clinical
- Stichting TRICALS Foundation
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Barcelona, Spain , Berlin, Germany , Bilbao, Spain , Bydgoszcz, Poland , Cagliari, Italy , Dresden, Germany , Dublin, Ireland , Hanover, Germany , Krakow, Poland , Leuven, Belgium and 25 more locations